SENSOPAD

SENSOPAD initiative heralds a transformative era in women's health by addressing the longstanding challenges posed by Endometriosis (ED). ED's early detection is often underdiagnosed due to its asymptomatic nature, pivotal for improved health outcomes and reduced healthcare costs. SENSOPAD introduces two pioneering ED sensing systems: sensoPAD, seamlessly integrated into sanitary pads, and sensoMFgFET, a portable Point-of-Care (POC) device. SensoPAD comprises three Biological Processing Units (BPU) - BPU-1, BPU-2, and BPU-3 - ensuring continuous monitoring. BPU-1 combines an electrochemical sensor with RFID, while BPU-2 merges a chemical-based fuel cell with an electrochromic cell. BPU-3, an energetically autonomous unit, synergizes BPU-1 and BPU-2 capabilities for seamless monitoring. SensoMFgFET, a POC device, utilizes microfluidic systems and bio-conjugated gFET with RFID functionality, capturing specific DNA SNPs from the menstrual fluid as early ED indicators. Both devices are complemented by a user-friendly mobile application enabling real-time data acquisition and analysis. An advanced cloud platform integrated with AI enhances diagnostic accuracy. This innovative approach shifts the paradigm in ED detection, empowering women, clinicians, and healthcare systems. SensoPAD detects biomarkers, providing insights during menstrual cycles. If concerns arise during its use, users transition to sensoMFgFET at clinical points, combining at-home convenience with clinical precision. SENSOPAD aims to reduce ED diagnosis time from eight years to days, enabling early treatment, preventing symptom deterioration, optimizing infertility care, and streamlining healthcare journeys. Integrating SENSOPADs with a mobile app and AI-enriched cloud platform ensures accurate, cost-effective diagnostics, detecting silent instances of ED, and signifies a paradigm shift, fostering informed, proactive, and inclusive healthcare decisions for women worldwide.